This study is in progress, not accepting new patients
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- ID
- NCT03900429
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1759 people participating
- Last Updated